News/Events

Leuven (Belgium), Strasbourg (France), Philadelphia (USA) – June 2, 2024 /PRNewswire/- Flamingo Therapeutics (“Flamingo”) today announced the presentation of a Trial-in-Progress poster at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO 2024) taking place in Chicago, Illinois.

Flamingo’s lead oncology program, danvatirsen, is an oligonucleotide discovered by Ionis that selectively targets STAT3 and has shown clinical activity in HNSCC.  PEMDA-HN (NCT05814666) is a multicenter, open-label, randomized study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic HNSCC whose tumor expresses PD-L1. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.  The primary endpoint of the study is overall response rate by RECIST 1.1 as assessed by the investigator. The secondary endpoints include safety, duration of response, disease control rate, progression free survival and overall survival.  PEMDA-HN is being conducted at study centers in the United States, South Korea and the United Kingdom.

ASCO poster details are as follows:

Abstract#: TPS6113
Title: “PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC)”
Session Title: Poster Session – Head and Neck Cancer
Session Date and Time: June 2, 2024, 9:00am CDT
Presenting Author: Marshall R. Posner, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

For more information, please visit the ASCO 2024 website.